FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma : vi

This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.

Related Keywords

United States , Texas , Meghan Gutierrez , Michael Wang , Eli Lilly , University Of Texas Md Anderson Cancer Center , Drug Administration , Lymphoma Research Foundation , Cancer Center , Medwatch Reporting System , Mantle Cell Lymphoma , Lymphoma , Malignant Lymphoma , Refractory , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Atrial Fibrillation , F Atrial Fibrillation , Cancer , Alignant Neoplasia , Arcinoma , Diarrhea , Dyspnea , Bedema , Fatigue , Hemorrhage , Bleeding , Lymphyocytes , Neutrophils , Orphan Drugs , Spain , Platelet Count , Latelet Count Plt , Hrombocyte Count , Platelets , Hromboc ,